It’s Rare Disease Day
Worldwide, 473 million people suffer from a rare disease1. But every single one of these diseases is not frequent at all – with some just occurring in a handful of patients. Regulatory pathways and incentives for drug development in rare diseases have facilitated the development of drugs for these indications, both by large pharma companies as well as by many biotechs. In today’s blog […]
Targeting Drug Effects in IPF
In the first two parts of our blog series on drug delivery in idiopathic pulmonary fibrosis (IPF), we focused on inhalation. In this third instalment, we showcase alternative approaches to focusing drug effects to the lung. As we mentioned previously, in the future treatment of IPF, new approaches will need to be compatible, at least initially, with the drugs used currently as “standards of care” (SoC). […]